HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Negative 62.1%

Neg 62.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma (NASDAQ:VOR) with a Buy and lowers the price target from $32 to $31.